Advertisement

Topics

Ritter Pharmaceuticals Reports Further Analysis from its Phase 2b/3 Trial Results Demonstrating ...

09:30 EDT 3 Aug 2017 | BioMedReports - Blog

Analysis shows clinically meaningful benefit from symptoms, global patient-reported and real-world assessments

LOS ANGELES, CA--(Marketwired - Aug 3, 2017) - Ritter Pharmaceuticals, Inc. (

Read more...

Original Article: Ritter Pharmaceuticals Reports Further Analysis from its Phase 2b/3 Trial Results Demonstrating ...

NEXT ARTICLE

More From BioPortfolio on "Ritter Pharmaceuticals Reports Further Analysis from its Phase 2b/3 Trial Results Demonstrating ..."

Quick Search
Advertisement